Previous 10 | Next 10 |
CohBar (NASDAQ: CWBR ): Q2 GAAP EPS of -$0.07. Press Release More news on: CohBar, Inc., Earnings news and commentary, Healthcare stocks news, ,
Company to host conference call and webcast today, August 7 th , at 5:00 p.m. EDT MENLO PARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and...
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its second quarter 2019 financial res...
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company focused on developing mitochondria based therapeutics to treat age-related diseases, today announced its poster presentation is available on the preclinical data on a fa...
MENLO PARK, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, is hosting its Annual Shareholder Meeting and Investor Update on Jun...
Gainers: Castor Maritime (NASDAQ: CTRM ) +39% . CohBar (NASDAQ: CWBR ) +29% . BIOLASE (NASDAQ: BIOL ) +25% . Regional Health Properties (NYSEMKT: RHE ) +25% . Basic Energy Services (NYSE: BAS ) +24% . Soliton (NASDAQ: SOLY ) +21% . CEL-SCI Corporation (NYSEMKT: CVM ) +21% . Su...
MENLO PARK, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, today announced that it will present its data on a family of novel a...
CohBar Inc. (CWBR) Q1 2019 Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Glenn Garmont – LifeSci Advisors Philippe Calais – Interim Chief Executive Officer Ken Cundy – Chief Scientific Officer Jeff Biunno – Chief Financial Offi...
MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today reported its financial results for the first quarter en...
MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, announced today that it has appointed Steven B. Engle as its ...
News, Short Squeeze, Breakout and More Instantly...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...